MET and chronic myelogenous leukemia, BCR-ABL1 positive: Collectively, these results indicate that activation of the MET/ERK and MET/JNK pathways may be involved in BCR-ABL1 TKI resistance, and inhibition of the MET/ERK and MET/JNK pathways can resensitize resistant CML cells to BCR-ABL1 TKIs.